Exploring the efficacy and future prospects of nutritional and dietary therapies in Crohn's disease.

IF 2.5 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY
Takayuki Yamamoto
{"title":"Exploring the efficacy and future prospects of nutritional and dietary therapies in Crohn's disease.","authors":"Takayuki Yamamoto","doi":"10.1080/17474124.2026.2667874","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Nutritional therapy has progressed from supportive care to a targeted strategy in inflammatory bowel disease (IBD), particularly Crohn's disease (CD). Exclusive enteral nutrition (EEN) is firmly established as a first-line induction therapy in pediatric CD, achieving remission rates comparable to corticosteroids while simultaneously supporting growth and promoting mucosal healing.</p><p><strong>Areas covered: </strong>This review outlines enteral and dietary interventions in CD. A PubMed (MEDLINE) search identified relevant studies on nutritional and dietary interventions in CD published up to 17 August 2025. In children, EEN is validated; in adults, its use is more selective, with evidence supporting benefit in mild-to-moderate disease, intolerance to pharmacologic agents, and perioperative optimization. Elemental or low-residue formulas are particularly relevant for patients with stricturing disease or malnutrition. Partial enteral nutrition and structured exclusion diets, such as the Crohn's Disease Exclusion Diet (CDED), offer feasible long-term approaches. Regional differences persist, as Japan has established reimbursement pathways facilitating enteral nutrition, whereas Western countries generally prioritize pharmacologic therapies.</p><p><strong>Expert opinion: </strong>Enteral nutrition remains a valuable therapeutic option in CD when applied to carefully selected patients. Although biologics and small molecules dominate current management, individualized patient selection, adherence support, and multidisciplinary education are critical to maximize its therapeutic impact.</p>","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"1-13"},"PeriodicalIF":2.5000,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474124.2026.2667874","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Nutritional therapy has progressed from supportive care to a targeted strategy in inflammatory bowel disease (IBD), particularly Crohn's disease (CD). Exclusive enteral nutrition (EEN) is firmly established as a first-line induction therapy in pediatric CD, achieving remission rates comparable to corticosteroids while simultaneously supporting growth and promoting mucosal healing.

Areas covered: This review outlines enteral and dietary interventions in CD. A PubMed (MEDLINE) search identified relevant studies on nutritional and dietary interventions in CD published up to 17 August 2025. In children, EEN is validated; in adults, its use is more selective, with evidence supporting benefit in mild-to-moderate disease, intolerance to pharmacologic agents, and perioperative optimization. Elemental or low-residue formulas are particularly relevant for patients with stricturing disease or malnutrition. Partial enteral nutrition and structured exclusion diets, such as the Crohn's Disease Exclusion Diet (CDED), offer feasible long-term approaches. Regional differences persist, as Japan has established reimbursement pathways facilitating enteral nutrition, whereas Western countries generally prioritize pharmacologic therapies.

Expert opinion: Enteral nutrition remains a valuable therapeutic option in CD when applied to carefully selected patients. Although biologics and small molecules dominate current management, individualized patient selection, adherence support, and multidisciplinary education are critical to maximize its therapeutic impact.

探讨营养和饮食治疗克罗恩病的疗效和未来前景。
营养治疗已经从支持治疗发展成为炎症性肠病(IBD),特别是克罗恩病(CD)的靶向治疗策略。独家肠内营养(EEN)是儿科CD的一线诱导治疗,在支持生长和促进粘膜愈合的同时,达到与皮质类固醇相当的缓解率。涵盖领域:本综述概述了乳糜泻的肠内和饮食干预措施。PubMed (MEDLINE)检索确定了截至2025年8月17日发表的有关乳糜泻营养和饮食干预措施的相关研究。在儿童中,EEN是有效的;在成人中,它的使用更具选择性,有证据支持对轻中度疾病、对药物不耐受和围手术期优化的益处。单质或低残留配方尤其适用于患有狭窄性疾病或营养不良的患者。部分肠内营养和结构性排他性饮食,如克罗恩病排他性饮食(CDED),提供了可行的长期方法。地区差异仍然存在,日本已经建立了促进肠内营养的报销途径,而西方国家通常优先考虑药物治疗。专家意见:肠内营养仍然是一种有价值的治疗选择,如果应用于精心挑选的患者。虽然生物制剂和小分子在目前的治疗中占主导地位,但个体化患者选择、依从性支持和多学科教育对于最大限度地发挥其治疗效果至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Expert Review of Gastroenterology & Hepatology
Expert Review of Gastroenterology & Hepatology GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
6.80
自引率
2.60%
发文量
86
审稿时长
6-12 weeks
期刊介绍: The enormous health and economic burden of gastrointestinal disease worldwide warrants a sharp focus on the etiology, epidemiology, prevention, diagnosis, treatment and development of new therapies. By the end of the last century we had seen enormous advances, both in technologies to visualize disease and in curative therapies in areas such as gastric ulcer, with the advent first of the H2-antagonists and then the proton pump inhibitors - clear examples of how advances in medicine can massively benefit the patient. Nevertheless, specialists face ongoing challenges from a wide array of diseases of diverse etiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书